Form 13-F position report

FIRST TRUST NYSE ARCA BIOTECHN

Reported by Yarbrough Capital LLC

ETF profile Manager portfolio Source filing
FBT CUSIP 33733E203 Manager CIK 0001767686
Latest reported change

Reported 31,160 shares, unchanged from the prior quarter.

Reported value -1.2%; share count 0.0% vs. the prior quarter.

Unchanged
% of reported 13F value 0.27% This manager · Q2 2023
Shares 31,160 Quarter-end amount reported
Reported value $4,771,842 Fair value at quarter end
Consecutive quarters held 7 Through Q2 2023

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Manager history

Quarterly position history

How this manager's reported quarter-end position changed over time.

16 quarters
Quarter Activity Shares Change % of reported 13F Reported value Filed
Q3 2025 Reduced 0 -31,160 (-100.0%) 0 $0 2025-10-20
Q2 2025 Unchanged 31,160 0 (0.0%) 0.18% $5,027,043 2025-07-15
Q1 2025 Unchanged 31,160 0 (0.0%) 0.23% $5,300,783 2025-04-14
Q4 2024 Unchanged 31,160 0 (0.0%) 0.2% $5,179,104 2025-01-15
Q3 2024 Unchanged 31,160 0 (0.0%) 0.22% $5,357,339 2024-10-15
Q2 2024 Unchanged 31,160 0 (0.0%) 0.2% $4,798,328 2024-07-17
Q1 2024 Unchanged 31,160 0 (0.0%) 0.21% $4,791,473 2024-04-10
Q4 2023 Unchanged 31,160 0 (0.0%) 0.26% $4,925,000 2024-01-12
Q3 2023 Unchanged 31,160 0 (0.0%) 0.27% $4,560,250 2023-10-12
Q2 2023 Unchanged 31,160 0 (0.0%) 0.27% $4,771,842 2023-07-13
Q1 2023 Unchanged 31,160 0 (0.0%) 0.39% $4,830,679 2023-04-13
Q4 2022 Unchanged 31,160 0 (0.0%) 0.38% $4,802,691 2023-01-12
Q3 2022 Unchanged 31,160 0 (0.0%) 0.33% $4,112,000 2022-11-03
Q2 2022 Unchanged 31,160 0 (0.0%) 0.32% $4,224,000 2022-07-08
Q1 2022 Unchanged 31,160 0 (0.0%) 0.26% $4,647,000 2022-04-14
Q4 2021 New 31,160 +31,160 (0.0%) 0.27% $5,047,000 2022-02-01
Institutional context

Who else reported the position

271 managers reported FIRST TRUST NYSE ARCA BIOTECHN for Q2 2023.

Manager Activity Shares Change % of reported 13F Reported value Tenure
MORGAN STANLEY Added 845,761 +69,331 0.01% $129,519,873 41 qtrs
WELLS FARGO & COMPANY MN Reduced 445,817 -71,083 0.02% $68,272,277 41 qtrs
Bank of America Corporation Reduced 357,903 -12,854 < 0.01% $54,809,273 41 qtrs
UBS Group AG Reduced 276,935 -78,643 0.01% $42,409,826 35 qtrs
Raymond James Financial Services Advisors Inc Reduced 244,721 -12,840 0.07% $37,476,610 39 qtrs
ROYAL BANK OF CANADA Reduced 227,441 -3,898 < 0.01% $34,830,000 41 qtrs
LPL Financial LLC Added 196,761 +5,264 0.02% $30,131,959 41 qtrs
RAYMOND JAMES & ASSOCIATES Reduced 131,901 -18,956 0.02% $20,199,318 41 qtrs
Berger Financial Group Inc Added 110,418 +1,493 1.92% $16,909,413 11 qtrs
ADVISOR GROUP HOLDINGS INC Added 98,886 +590 0.03% $15,133,311 14 qtrs
A free account expands this comparison to 25 managers. Create free account
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
June 30, 2023
Filed
July 13, 2023
Filing type
13F-HR
Position type
NY ARCA BIOTECH

Voting authority reported

Sole
0
Shared
0
None
31,160

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.